Research use only, not for human consumption. Email [email protected]
← Research status explorer
Ignite / Metabolic

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

Current research status Approved Molecule*
Extensive clinical development
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*

Overview

Semaglutide is a GLP-1 receptor agonist approved by the FDA under several brand names: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management and cardiovascular-risk reduction. It has one of the largest clinical trial programs of any peptide-derived drug, spanning cardiovascular, renal and metabolic outcome studies. As with every approved molecule on this list, approval covers specific branded products and indications, not research-grade material.

Key research

Last reviewed: September 2026

*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.